



Millie Das

Clinical Professor, Medicine - Oncology

 Curriculum Vitae available Online

CLINICAL OFFICE (PRIMARY)

- **Stanford Cancer Center**

875 Blake Wilbur Dr

MC 6560

Stanford, CA 94305

Tel (650) 498-6000 **Fax** (650) 725-9113

Bio

BIO

Dr. Das specializes in the treatment of thoracic malignancies. She sees and treats patients both at the Stanford Cancer Center and at the Palo Alto VA Hospital. She is Chief of Oncology at the Palo Alto VA and is an active member of the VA national Lung Cancer Working Group and Lung Cancer Precision Oncology Program. In 2023, she was elected President the Association of Northern California Oncologists (ANCO), where she displays her passion for patient advocacy and also for clinician education by helping to organize Bay Area focused continuing medical education programs. She is the VA site director for the Stanford fellowship program and leads the VA thoracic tumor board on a biweekly basis. She has a strong interest in clinical research, serving as a principal investigator for multiple clinical and translational studies at the Palo Alto VA, and also as a co-investigator on all of the lung cancer trials at Stanford. In her free time, she enjoys spending time with her family, traveling, and running.

CLINICAL FOCUS

- Thoracic Oncology
- Medical Oncology

ACADEMIC APPOINTMENTS

- Clinical Professor, Medicine - Oncology
- Member, Stanford Cancer Institute

ADMINISTRATIVE APPOINTMENTS

- Chief, Oncology, VA Palo Alto Health Care System, (2015- present)
- Associate Program Director, Oncology Fellowship, Stanford University, (2015- present)

BOARDS, ADVISORY COMMITTEES, PROFESSIONAL ORGANIZATIONS

- Member, International Association for the Study of Lung Cancer (IASLC) (2009 - present)
- Member, American Society of Clinical Oncology (ASCO) (2008 - present)

PROFESSIONAL EDUCATION

- Fellowship, Stanford University Hematology and Oncology Fellowship , CA (2011)
- Board Certification: Medical Oncology, American Board of Internal Medicine (2011)
- Residency: Stanford University Hospital -Clinical Excellence Research Center (2007) CA
- Internship: Stanford University Hospital -Clinical Excellence Research Center (2005) CA
- Medical Education: University of Massachusetts Medical Center (2004) MA

LINKS

- Get a Second Opinion: <https://stanfordhealthcare.org/second-opinion/overview.html>

Research & Scholarship

CLINICAL TRIALS

- Expanded Treatment Protocol LDK378 in NSCLC Characterized by ALK Positivity, Not Recruiting
- LUNGMAP: MasterProtocol Evaluating Biomarker-Driven Therapies &Immuno-Tx In Previously-Treated NSCLC, Not Recruiting
- Phase I ACOOIOMA in Previously Treated EGFRmut & Acquired T790M Mutation Non-Small Cell Lung Cancer, Not Recruiting
- Phase I AZD9291 & Necitumumab in EGFR-Mutant NSCLC After Progression on Previous EGFR TKI, Not Recruiting
- Phase I MAGE-A10c796T in Stage IIIb / IV Non-Small Cell Lung Cancer, Not Recruiting
- Phase I/II BTK Inhibitor Ibrutinib in Combo with Durvalumab in Relapsed or Refractory Solid Tumors, Not Recruiting
- Phase I/II Cisplatin + Etoposide plus Veliparib (ABT-888) or Placebo in Extensive Stage SCLC, Not Recruiting
- Phase I/II MEDI4736 in Advanced Solid Tumors, Not Recruiting
- Phase I/II X-396 in Advanced Solid Tumors & Expansion Phase in ALK+ Non-Small Cell Lung Cancer , Not Recruiting
- Phase Ib PDR001 in Combo w/ Platinum-Doublet Chemotherapy & Other Agents in PD-L1 Metastatic NSCLC, Not Recruiting
- Phase II Atezolizumab in PD-L1-Positive Locally Advanced or Metastatic NSCLC, Not Recruiting
- Phase II Concise vs Prolonged Adjuvant Afatinib in Resected Stage I-III NSCLC with EGFR Mutation, Not Recruiting
- Phase II Etirinotecan Pegol in Refractory Brain Metastases & Advanced Lung CA / Metastatic Breast CA, Not Recruiting
- Phase II Individualized Combined Modality Therapy for Stage III NSCLC, Not Recruiting
- Phase II Oral Ceritinib Tx in ALK-Positive NSCLC Metastatic to the Brain and/or to Leptomeninges, Not Recruiting
- Phase II Pembrolizumab in Metastatic NSCLC Examining Circulating Tumor DNA Levels, Not Recruiting
- Phase III Atezolizumab (Anti-PD-L1 Antibody) vs Best Supportive Care in Non Small Cell Lung Cancer, Not Recruiting
- Phase III Nab-Paclitaxel in Maint Tx After Induction w/Nab-Paclitaxel +Carboplatin in Squamous NSCLC, Not Recruiting
- Phase III Nivolumab vs Investigator's Choice Chemo in Stage IV /Recurrent PD-L1+ NSCLC , Not Recruiting
- Screening for Tumor Antigen Expression Profiling & HLA Typing in Solid & Hematological Malignancies, Not Recruiting
- Biomarker Directed Trial of Temozolomide and Stenoparib in Relapsed SCLC, Not Specified

Publications

PUBLICATIONS

- **Central Nervous System Progression in Patients Receiving ALK-Targeted Central Nervous System-Penetrable Tyrosine Kinase Inhibitors: Treatment Patterns and Outcomes (vol 6, 100914, 2025) JTO CLINICAL AND RESEARCH REPORTS**
Singhal, S., Hui, C., Neal, J. W., Nagpal, S., Roy, M., Das, M., Ramchandran, K., Pollom, E., Selvaggi, G., Wakelee, H. A., Myall, N. J.
2026; 7 (6)

- **Corrigendum to 'Central Nervous System Progression in Patients Receiving ALK-Targeted Central Nervous System-Penetrable Tyrosine Kinase Inhibitors: Treatment Patterns and Outcomes' [JTO Clinical and Research Reports 6 (2025) 100914].** *JTO clinical and research reports*
Singhal, S., Hui, C., Neal, J. W., Nagpal, S., Roy, M., Das, M., Ramchandran, K., Pollom, E., Selvaggi, G., Wakelee, H. A., Myall, N. J.
2026; 7 (6): 100992
- **Mitochondrial Imaging Detects Early Cardiac Changes Following Cancer Immunotherapy.** *Clinical cancer research : an official journal of the American Association for Cancer Research*
Chae, H. D., Shrestha, U., Das, M., Vasanaawala, M. S., Behl, D., Davar, D., Srinivas, S., Colevas, A. D., Sunwoo, J. B., Del Mar, N., Pierini, M., Guillen, M., Garcia, et al
2026
- **Things You Should Know About Treating Paraneoplastic Lambert-Eaton Myasthenic Syndrome** *ONCOLOGY-NEW YORK*
Das, M., Iams, W., Nasany, R.
2026; 40 (2): 146-149
- **DLL3 Immunohistochemical Expression in Neuroendocrine-Transformed EGFR-Mutant Lung Cancer and Two Cases of Tarlatamab Therapy** *JTO CLINICAL AND RESEARCH REPORTS*
V. Aredo, J., Singhal, S., Berry, G. J., Moradi, F., Wakelee, H. A., Myall, N. J., Ramchandran, K. J., Das, M., Suarez, C. J., Neal, J. W., Riess, J. W.
2025; 6 (12)
- **Central Nervous System Progression in Patients Receiving ALK-Targeted Central Nervous System-Penetrable Tyrosine Kinase Inhibitors: Treatment Patterns and Outcomes.** *JTO clinical and research reports*
Singhal, S., Hui, C., Neal, J. W., Nagpal, S., Roy, M., Das, M., Ramchandran, K., Pollom, E., Selvaggi, G., Wakelee, H. A., Myall, N. J.
2025; 6 (12): 100914
- **DLL3 Immunohistochemical Expression in Neuroendocrine-Transformed EGFR-Mutant Lung Cancer and Two Cases of Tarlatamab Therapy.** *JTO clinical and research reports*
Aredo, J. V., Singhal, S., Berry, G. J., Moradi, F., Wakelee, H. A., Myall, N. J., Ramchandran, K. J., Das, M., Suarez, C. J., Neal, J. W., Riess, J. W.
2025; 6 (12): 100913
- **Central Nervous System Progression in Patients Receiving ALK-Targeted Central Nervous System- Penetrable Tyrosine Kinase Inhibitors: Treatment Patterns and Outcomes** *JTO CLINICAL AND RESEARCH REPORTS*
Singhal, S., Hui, C., Neal, J. W., Nagpal, S., Roy, M., Das, M., Ramchandran, K., Pollom, E., Selvaggi, G., Wakelee, H. A., Myall, N. J.
2025; 6 (12)
- **Brief Report: Safety of Pulse-Dose Osimertinib for Treatment of Leptomeningeal Disease or Refractory Brain Metastases in EGFR-Mutated Non-small Cell Lung Cancer** *CLINICAL LUNG CANCER*
Sun, F., Nagpal, S., Singhal, S., Neal, J. W., Wakelee, H. A., Myall, N. J., Bolan, P., Riess, J. W., Gandara, D. R., Das, M. S.
2025; 26 (7)
- **Systemic mitochondrial alterations in patients with advanced non-small lung cancer revealed by [18F]F-AraG PET imaging**
Levi, J., Shrestha, U., Das, M., Vasanaawala, M., Behl, D., Sayre, J., Cabrera, H., Gullen, M., Pierini, M., Blecha, J., Vanbrocklin, H., Seo, Y., Chae, et al
ELSEVIER.2025
- **Effect of a Volunteer-Led Precision-Medicine Multilevel Intervention on Patient-Reported Outcomes, Receipt of Biomarker Testing, and Time to Treatment: A Randomized Clinical Trial.** *JCO oncology practice*
Thomas, M., Agrawal, M., Das, M., Patel, M. I.
2025: OP2500531
- **Clinical factors and molecular co-alterations impact outcomes in patients receiving first-line osimertinib for EGFR-mutated non-small cell lung cancer.** *Lung cancer (Amsterdam, Netherlands)*
Sun, F., Banwait, M. K., Singhal, S., Herrmann, A., Piotrowska, Z., Yun, K., Bazhenova, L., Ullah, A. T., Guo, E. W., Wakelee, H. A., Neal, J. W., Das, M. S., Ramchandran, et al
2025; 208: 108747
- **Integrated molecular and clinical characterization of pulmonary large cell neuroendocrine carcinoma.** *Nature communications*
Nassar, A. H., Kim, C., Adeyelu, T., Bou Farhat, E., Abushukair, H., Rakaee, M., Matteson, K., Lau, S., Takabe, Y., Ocejo, A., Ardeshir-Larijani, F., Leal, T., Ramalingam, et al
2025; 16 (1): 7717

- **Brief Report: Safety of Pulse-Dose Osimertinib for Treatment of Leptomeningeal Disease or Refractory Brain Metastases in EGFR-Mutated Nonsmall Cell Lung Cancer.** *Clinical lung cancer*
Sun, F., Nagpal, S., Singhal, S., Neal, J. W., Wakelee, H. A., Myall, N. J., Bolan, P., Riess, J. W., Gandara, D. R., Das, M. S.
2025
- **Smoking Trends in KRAS-Mutated Non-Small Cell Lung Cancer at a Tertiary Referral Center**
Aredo, J., Neal, J. W., Ramchandran, K. J., Das, M. S., Myall, N. J., Wakelee, H. A.
ELSEVIER SCIENCE INC.2025
- **Molecular Markers in the Era of Precision Care in Lung Cancer.** *Seminars in respiratory and critical care medicine*
Paranjpe, I., Salter, A., Chen, K., Das, M.
2025
- **Integrating ctDNA Analysis and Radiomics for Dynamic Risk Assessment in Localized Lung Cancer.** *Cancer discovery*
Moding, E. J., Shahrokh Esfahani, M., Jin, C., Hui, A. B., Nabet, B. Y., Liu, Y., Chabon, J. J., Binkley, M. S., Kurtz, D. M., Hamilton, E. G., Chaudhuri, A. A., Liu, C. L., Li, et al
2025: OF1-OF21
- **Targeting the EZH2-SLFN11 pathway-a lesson in developing molecularly-informed treatments for recurrent small cell lung cancer.** *Translational cancer research*
Sun, F., Das, M. S.
2024; 13 (12): 6608-6612
- **Correction: The performance status gap in immunotherapy for frail patients with advanced non-small cell lung cancer.** *Cancer immunology, immunotherapy : CII*
Wu, J. T., Corrigan, J., Su, C., Dumontier, C., La, J., Khan, A., Arya, S., Harris, A. H., Backhus, L., Das, M., Do, N. V., Brophy, M. T., Han, et al
2024; 74 (1): 34
- **Systemic Therapy for Small Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update Clinical Insights.** *JCO oncology practice*
Khurshid, H., Ismaila, N., Das, M., Kulkarni, S., Manochakian, R., Weinberg, F., Kalemkerian, G. P.
2024: OP2400840
- **[18F]F-AraG Uptake in Vertebral Bone Marrow May Predict Survival in Patients with Non-Small Cell Lung Cancer Treated with Anti-PD-(L)1 Immunotherapy.** *Journal of nuclear medicine : official publication, Society of Nuclear Medicine*
Levi, J., Das, M., Vasawala, M. S., Behl, D., Pomper, M., Forde, P. M., Nakajima, E., Sayre, J., Shen, B., Cabrera, H., Del Mar, N., Gullen, M., Pierini, et al
2024
- **A Phase 2 Single-Arm Trial of High-Dose Radiotherapy Added to Immunotherapy for Patients with Metastatic Non Small Cell Lung Cancer**
Kotha, N. V., Vitzthum, L., Chin, A. L., Jackson, S., Pratapneni, A., Le-Budka, M. L., Brown, E., Barnick, K., Wakelee, H. A., Das, M., Ramchandran, K. J., Myall, N., Padda, et al
ELSEVIER SCIENCE INC.2024: S60
- **First-Line Treatments for Advanced Pure Large Cell Neuroendocrine Tumors (LCNEC):Insights from a Global Clinico-Genomic Study**
Nassar, A. H., Matteson, K., Adeyelu, T., Ocejjo, A., Ardeshir, F., Leal, T., Ramalingam, S., Gray, J. E., Hicks, K., Kaldas, D., Baena, J., Berjaga, M., Kwiatkowski, et al
ELSEVIER SCIENCE INC.2024: S358-S359
- **Central Nervous System (CNS) Progression on CNS Penetrable ALK TKI: Real-World Practice Patterns and Patient Outcomes**
Singhal, S., Hui, C., Neal, J., Roy, M., Das, M., Ramchandran, K., Pollom, E., Selvaggi, G., Wakelee, H., Myall, N.
ELSEVIER SCIENCE INC.2024: S200-S201
- **Effect of De Novo Co-Mutations on Clinical Outcomes in Patients Receiving First-Line Osimertinib for EGFRMutated NSCLC**
Sun, F., Banwait, M. K., Herrmann, A., Piotrowska, Z., Yun, K., Bazhenova, L. A., Wakelee, H. A., Neal, J. W., Das, M. S., Ramchandran, K. J., Roy, M., Diehn, M., Myall, et al
ELSEVIER SCIENCE INC.2024: S196-S197
- **A phase 2 single-arm trial of high-dose precision targeted radiotherapy added to immunotherapy for patients with metastatic non-small cell lung cancer.** *International journal of radiation oncology, biology, physics*
Gensheimer, M. F., Kotha, N. V., Vitzthum, L. K., Chin, A. L., Jackson, S., t Erve, I. v., Pratapneni, A., Le-Budka, M. L., Wong, S., Brown, E., Barnick, K., Wakelee, H. A., Das, et al

2024

- **ROS1-rearranged non-small cell lung cancer: Understanding biology and optimizing management in the era of new approvals.** *Current problems in cancer*
Myall, N. J., Das, M.
2024; 53: 101133
- **The performance status gap in immunotherapy for frail patients with advanced non-small cell lung cancer.** *Cancer immunology, immunotherapy : CII*
Wu, J. T., Corrigan, J., Su, C., Dumontier, C., La, J., Khan, A., Arya, S., Harris, A. H., Backhus, L., Das, M., Do, N. V., Brophy, M. T., Han, et al
2024; 73 (9): 172
- **Teleoncology in the Veterans Health Administration: Models of Care and the Veteran Experience.** *American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting*
Parikh, D. A., Rodgers, T. D., Passero, V. A., Chang, J. C., Tisdale, R., Kelley, M. J., Das, M.
2024; 44 (3): e100042
- **Ensuring precision medicine for veterans with lung cancer: A randomized clinical trial**
Thomas, M., Gonzalez, H., Agrawal, M., Das, M., Patel, M. I.
LIPPINCOTT WILLIAMS & WILKINS.2024
- **Novel immunotherapy combinations in neoadjuvant non-small cell lung cancer (NSCLC): a better chance at cure?** *Translational lung cancer research*
Salter, A. I., Das, M.
2024; 13 (3): 673-677
- **Randomized Trial of a Volunteer-Led Symptom Assessment Intervention on Documentation, Patient-Reported Outcomes, and Health Care Use Among Veterans With Lung Cancer.** *JCO oncology practice*
Banks, L. C., Kapphahn, K., Das, M., Patel, M. I.
2024: OP2300557
- **UHL1 is a potential molecular indicator and therapeutic target for neuroendocrine carcinomas.** *Cell reports. Medicine*
Liu, S., Chai, T., Garcia-Marques, F., Yin, Q., Hsu, E. C., Shen, M., Shaw Toland, A. M., Bermudez, A., Hartono, A. B., Massey, C. F., Lee, C. S., Zheng, L., Baron, et al
2024: 101381
- **Patient Selection and Outcomes for Hypofractionated Accelerated Radiation and Concurrent Chemotherapy for Non-Small-Cell Lung Cancer.** *Clinical lung cancer*
Hui, C., Marquez, C., Lau, B., Das, M., Myall, N. J., Roy, M., Wakelee, H. A., Neal, J. W., Kovalchuk, N., Chin, A., Diehn, M., Loo, B. W., Xiang, et al
2023
- **Personalized Accelerated ChEmoRadiation (PACER) for Lung Cancer: Protocol for a Bayesian Optimal Phase I/II Trial.** *Clinical lung cancer*
Hui, C., Brown, E., Wong, S., Das, M., Wakelee, H., Neal, J., Ramchandran, K., Myall, N. J., Pham, D., Xing, L., Yang, Y., Kovalchuk, N., Yuan, et al
2023
- **Molecular Distribution of Patients with Non-Small Cell Lung Cancer Eligible for Lung Cancer Screening**
Aredo, J. V., Neal, J. W., Kunder, C. A., Ramchandran, K. J., Das, M. S., Myall, N. J., Han, S. S., Wakelee, H. A.
ELSEVIER SCIENCE INC.2023: S102-S103
- **Systemic Therapy for Small-Cell Lung Cancer: ASCO-Ontario Health (Cancer Care Ontario) Guideline.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
Khurshid, H., Ismaila, N., Bian, J., Dabney, R., Das, M., Ellis, P., Feldman, J., Hann, C., Kulkarni, S., Laskin, J., Manochakian, R., Mishra, D. R., Preeshagul, et al
2023: JCO2301435
- **Crosstalk between small-cell lung cancer cells and astrocytes mimics brain development to promote brain metastasis.** *Nature cell biology*
Qu, F., Brough, S. C., Michno, W., Madubata, C. J., Hartmann, G. G., Puno, A., Drains, A. P., Bhattacharya, D., Tomasich, E., Lee, M. C., Yang, D., Kim, J., Peiris-Pagès, et al
2023
- **CNS Control after First-Line Osimertinib in Patients with Metastatic EGFR-Mutant NSCLC.** *International journal of radiation oncology, biology, physics*

Hui, C., Wakelee, H. A., Neal, J. W., Ramchandran, K. J., Das, M., Nagpal, S., Roy, M., Huang, J., Pollom, E., Myall, N.
2023; 117 (2S): e110

- **Understanding Barriers and Facilitators to High-Quality Cancer Care Among Veterans With Lung Cancer: A Qualitative Study.** *JCO oncology practice*
Lopez, C., Murillo, A., Das, M., Patel, M. I.
2023: OP2300228
- **Individualized Stereotactic Ablative Radiotherapy for Lung Tumors: The iSABR Phase 2 Nonrandomized Controlled Trial.** *JAMA oncology*
Gensheimer, M. F., Gee, H., Shirato, H., Taguchi, H., Snyder, J. M., Chin, A. L., Vitzthum, L. K., Maxim, P. G., Wakelee, H. A., Neal, J., Das, M., Chang, D. T., Kidd, et al
2023
- **Small Cell Lung Cancer: Emerging Targets and Strategies for Precision Therapy.** *Cancers*
Patel, S. R., Das, M.
2023; 15 (16)
- **Amivantamab vs Mobocertinib in Exon 20 NSCLC** *ONCOLOGY-NEW YORK*
Spira, A. I., Bestvina, C., Sabari, J. K., Das, M., Nagasaka, M.
2023; 37 (8): 340-342
- **Are We Getting Closer to the Promise of Cure? New Progress and Future Directions in the Treatment of Early-Stage Non-Small-Cell Lung Cancer.** *JCO oncology practice*
Das, M.
2023: OP2300170
- **Pulmonary Hemorrhage in Patients Treated with Thoracic Stereotactic Ablative Radiotherapy and Anti-Angiogenic Agents.** *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer*
Lau, B., Wu, Y. F., No, H. J., Ko, R. B., Devine, M., Das, M. S., Neal, J. W., Wakelee, H. A., Ramchandran, K., Gensheimer, M. F., Diehn, M., Chin, A. L., Loo, et al
2023
- **Cost-effectiveness of adjuvant atezolizumab for patients with stage II-IIIa PD-L1+ non-small-cell lung cancer.** *Immunotherapy*
Das, M., Ogale, S., Jovanoski, N., Johnson, A., Nguyen, C., Bhagwakar, J., Lee, J. S.
2023
- **Impact of PD-L1 Status on Survival on Immunotherapy Monotherapy in Real-World Patients with Poor Performance Status: A US Nationwide Veterans Affairs Study**
Wu, J., Su, C., La, J., Corrigan, J., Das, M., Do, N., Brophy, M., Ahmed, S., Han, S., Fillmore, N., Kelley, M.
ELSEVIER SCIENCE INC.2023: E11-E12
- **Use of Machine Learning and Lay Care Coaches to Increase Advance Care Planning Conversations for Patients With Metastatic Cancer.** *JCO oncology practice*
Gensheimer, M. F., Gupta, D., Patel, M. I., Fardeen, T., Hildebrand, R., Teuteberg, W., Seevaratnam, B., Asuncion, M. K., Alves, N., Rogers, B., Hansen, J., DeNofrio, J., Shah, et al
2022: OP2200128
- **Characterizing Metastatic Non-Small Cell Lung Cancer Presenting to an Academic Medical Center in an Era of Changing Treatment Paradigms**
Raja, N., No, H. J., Von Eyben, R., Das, M., Roy, M., Myall, N., Chin, A. L., Diehn, M., Loo, B. W., Chang, D. T., Pollom, E., Vitzthum, L.
ELSEVIER SCIENCE INC.2022: E407
- **Local Control of Brain Metastases with Osimertinib Alone in Patients with EGFR-Mutant Non-Small Cell Lung Cancer**
Hui, C., Qu, V., Wang, J. Y., Von Eyben, R., Chang, Y. C., Chiang, P. L., Liang, C. H., Lin, J. Y., Lu, J. T., Li, G., Hayden, M., Myall, N., Soltys, et al
ELSEVIER SCIENCE INC.2022: E54-E55
- **Regression of Malignant Pleural Mesothelioma in Absence of Chemotherapy or Surgery: A Case Series.** *Clinical lung cancer*
Nief, C. A., No, H. J., Louie, C. Y., Vitzthum, L., Das, M.
2022
- **Local control of brain metastases with osimertinib alone in patients with EGFR-mutant non-small cell lung cancer.** *Journal of neuro-oncology*

Hui, C., Qu, V., Wang, J. Y., von Eyben, R., Chang, Y. C., Chiang, P. L., Liang, C. H., Lu, J. T., Li, G., Hayden-Gephart, M., Wakelee, H., Neal, J., Ramchandran, et al
2022

- **Understanding the barriers and experiences of veterans with lung cancer**
Lopez, C., Murillo, A., Das, M., Patel, M. I.
LIPPINCOTT WILLIAMS & WILKINS.2022: 160
- **Early Outcomes and Toxicity with Concurrent Chemotherapy and Hypofractionated Radiation Therapy in Patients with Non-Small Cell Lung Cancer**
Hui, C., Marquez, C., Lau, B., Von Eyben, R., Das, M., Myall, N., Roy, M., Chin, A., Diehn, M., Loo, B., Vitzthum, L.
LIPPINCOTT WILLIAMS & WILKINS.2022: S44
- **The Impact of Current Smoking Status at Initiation of Immune Checkpoint Inhibitor Therapy on Tumor Mutation Burden and Survival**
Wu, J. T., La, J., Han, S., Das, M., Glover, M., Scobie, M., Brophy, M., Do, N., Ahmed, S., Fillmore, N., Kelley, M.
ELSEVIER SCIENCE INC.2022: S359-S360
- **Cost-Effectiveness of Atezolizumab for Adjuvant Treatment of Patients with Stage II-III A PD-L1+Non-small Cell Lung Cancer**
Das, M., Ogale, S., Johnson, A., Nguyen, C., Bhagwakar, J., Jovanoski, N.
ELSEVIER SCIENCE INC.2022: S253
- **Improving Supportive Care for Patients with Thoracic Cancer**
Banks, L. C., Wujcik, D., Stricker, C., Das, M., Shanbhag, L., Lin, S., Patel, M.
ELSEVIER SCIENCE INC.2022: S261
- **Improving supportive care for patients with Thoracic Malignancies - A randomized controlled trial. *Contemporary clinical trials communications***
Patel, M. I., Banks, L., Das, M.
2022; 28: 100929
- **Isolated Nodal Recurrence After Definitive Stereotactic Ablative Radiotherapy for Non-Small Cell Lung Cancer. *Practical radiation oncology***
Devine, M., Merriott, D. J., No, H. J., Lau, B., Say, C., Yoo, C., Yi, E., Ko, R. B., Neal, J. W., Wakelee, H. A., Das, M., Loo, B. W., Diehn, et al
2022
- **Characterization of ERBB2 (HER2) Alterations in Metastatic Non-small Cell Lung Cancer and Comparison of Outcomes of Different Trastuzumab-based Regimens. *Clinical lung cancer***
Waliany, S., Wakelee, H., Ramchandran, K., Das, M., Huang, J., Myall, N., Li, C., Pagtama, J., Tisch, A. H., Neal, J. W.
2022
- **Improving supportive care for patients with thoracic cancer.**
Banks, L., Kappahn, K., Das, M., Wujcik, D., Stricker, C., Shanbhag, L., Stephanie, L., Zhu, G., Patel, M. I.
LIPPINCOTT WILLIAMS & WILKINS.2022
- **Characterization of Metastatic Non-Small Cell Lung Cancer and Oligometastatic Incidence in an Era of Changing Treatment Paradigms. *International journal of radiation oncology, biology, physics***
No, H. J., Raja, N., Von Eyben, R., Das, M., Roy, M., Myall, N., Neal, J., Wakelee, H., Chin, A., Diehn, M., Loo, B. W., Chang, D. T., Pollom, et al
2022
- **Biological and clinical correlates of the patient health questionnaire-9: exploratory cross-sectional analyses of the baseline health study. *BMJ open***
Califf, R. M., Wong, C., Doraiswamy, P. M., Hong, D. S., Miller, D. P., Mega, J. L.
2022; 12 (1): e054741
- **Chemotherapy Plus Immunotherapy Versus Chemotherapy Plus Bevacizumab Versus Chemotherapy Alone in EGFR-Mutant NSCLC After Progression on Osimertinib. *Clinical lung cancer***
White, M. N., Piper-Vallillo, A. J., Gardner, R. M., Cunanan, K., Neal, J. W., Das, M., Padda, S. K., Ramchandran, K., Chen, T. T., Sequist, L. V., Piotrowska, Z., Wakelee, H. A.
2021
- **Impact of Facility Treatment Volume on Stereotactic Ablative Radiotherapy (SABR) Outcomes in Early-Stage Non-Small Cell Lung Cancer (NSCLC). *International journal of radiation oncology, biology, physics***

Marar, M., Bryant, A. K., Nalawade, V., Das, M., Jr, B. W., Diehn, M., Chin, A. L., Murphy, J. D., Vitzthum, L.
2021; 111 (3S): e447

● **Impact of Facility Treatment Volume on Stereotactic Ablative Radiotherapy (SABR) Outcomes in Early-Stage Non-Small Cell Lung Cancer (NSCLC)**

Marar, M., Bryant, A. K., Nalawade, V., Das, M., Loo, B. W., Diehn, M., Chin, A. L., Murphy, J. D., Vitzthum, L.
ELSEVIER SCIENCE INC.2021: E447

● **A Phase II Trial of Individualized Stereotactic Ablative Radiotherapy for Lung Tumors (iSABR)**

Gensheimer, M. F., Gee, H. E., Von Eyben, R., Shirato, H., Taguchi, H., Wong, S., Brown, E., Nguyen, N., Liang, R., Maxim, P. G., Wakelee, H. A., Neal, J. W., Das, et al
ELSEVIER SCIENCE INC.2021: S89-S90

● **Patterns of Care in Patients With Isolated Nodal Recurrence After Definitive Stereotactic Ablative Radiotherapy for Non-Small Cell Lung Cancer**

Devine, M., Merriott, D. J., Say, C., Yoo, C., Yi, E., Lau, B., Ko, R. B., Shaheen, S., Neal, J. W., Wakelee, H. A., Das, M., Loo, B. W., Diehn, et al
ELSEVIER SCIENCE INC.2021: E435

● **Pulmonary Hemorrhage in Patients Treated With Thoracic Stereotactic Ablative Radiotherapy and Anti-Angiogenic Agents**

Lau, B., No, H. J., Wu, Y. F., Ko, R. B., Devine, M., Das, M., Neal, J. W., Ramchandran, K. J., Wakelee, H. A., Shaheen, S., Diehn, M., Chin, A. L., Loo, et al
ELSEVIER SCIENCE INC.2021: E423

● **A Phase II Trial of Individualized Stereotactic Ablative Radiotherapy for Lung Tumors (iSABR).** *International journal of radiation oncology, biology, physics*

Gensheimer, M. F., Gee, H. E., Von Eyben, R., Shirato, H., Taguchi, H., Wong, S., Brown, E., Nguyen, N., Liang, R., Maxim, P. G., Wakelee, H. A., Neal, J. W., Das, et al
2021; 111 (3S): S89-S90

● **Patterns of Care in Patients With Isolated Nodal Recurrence After Definitive Stereotactic Ablative Radiotherapy for Non-Small Cell Lung Cancer.** *International journal of radiation oncology, biology, physics*

Devine, M., Merriott, D. J., Say, C., Yoo, C., Yi, E., Lau, B., Ko, R. B., Shaheen, S., Neal, J. W., Wakelee, H. A., Das, M., Loo, B. W., Diehn, et al
2021; 111 (3S): e435

● **Impact of Tumor Suppressor Gene Co-Mutations on Differential Response to EGFR TKI Therapy in EGFR L858R and Exon 19 Deletion Lung Cancer.** *Clinical lung cancer*

Hellyer, J. A., White, M. N., Gardner, R. M., Cunanan, K., Padda, S. K., Das, M., Ramchandran, K., Neal, J. W., Wakelee, H. A.
2021

● **Pulmonary Hemorrhage in Patients Treated with Thoracic Stereotactic Ablative Radiotherapy and Anti-Angiogenic Agents**

Lau, B., No, H., (Fred) Wu, Y., Devine, M., Ko, R., Loo, B., Diehn, M., Chin, A., Vitzthum, L.
LIPPINCOTT WILLIAMS & WILKINS.2021: S105

● **Advances in Treatment of Recurrent Small Cell Lung Cancer (SCLC): Insights for Optimizing Patient Outcomes from an Expert Roundtable Discussion.** *Advances in therapy*

Das, M., Padda, S. K., Weiss, J., Owonikoko, T. K.
2021

● **Pharmacovigilance analysis of cardiac toxicities associated with targeted therapies for metastatic non-small cell lung carcinoma.** *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer*

Waliany, S., Zhu, H., Wakelee, H., Padda, S. K., Das, M., Ramchandran, K., Myall, N. J., Chen, T., Witteles, R. M., Neal, J. W.
2021

● **EGFR exon 20 Insertion NSCLC and Response to Platinum-Based Chemotherapy.** *Clinical lung cancer*

Shah, M. P., Aredo, J. V., Padda, S. K., Ramchandran, K. J., Wakelee, H. A., Das, M. S., Neal, J. W.
2021

● **Machine Learning Radiomics Model for Early Identification of Small-Cell Lung Cancer on Computed Tomography Scans.** *JCO clinical cancer informatics*

Shah, R. P., Selby, H. M., Mukherjee, P., Verma, S., Xie, P., Xu, Q., Das, M., Malik, S., Gevaert, O., Napel, S.
2021; 5: 746-757

- **Immune Checkpoint Inhibitor Pneumonitis: Heterogeneity in Clinical Management**
Filsoof, D., Padda, S. K., Garcia, P., Stedman, M., Neal, J. W., Wakelee, H. A., Ramchandran, K., Das, M., Ramsey, M., Bedi, H. S., Sung, A., Raj, R., Anand, et al
AMER THORACIC SOC.2021
- **Pragmatic Application of Computed Tomography Lung Texture Analysis in Immune Checkpoint Inhibitor Pneumonitis: An Exploratory Study**
Filsoof, D., Im, J., Garcia, P., Stedman, M., Anand, S., Neal, J. W., Wakelee, H. A., Ramchandran, K., Das, M., Padda, S. K., Sharifi, H., Mooney, J. J., Tsai, et al
AMER THORACIC SOC.2021
- **Chemotherapy with or without immunotherapy or bevacizumab for EGFR-mutated lung cancer after progression on osimertinib**
White, M., Neal, J. W., Gardner, R. M., Cunanan, K. M., Das, M., Padda, S. K., Ramchandran, K., Chen, T. T., Wakelee, H.
ELSEVIER SCIENCE INC.2021: S773–S774
- **Circulating tumor DNA kinetics to identify genomic predictors of rapid response to chemoradiation in non-small cell lung cancer.**
Moding, E. J., Liu, Y., Hui, A. B., He, J., Qiao, Y., Xu, T., Yao, L., Gandhi, S., Liao, Z., Das, M., Ramchandran, K. J., Padda, S. K., Neal, et al
AMER ASSOC CANCER RESEARCH.2021
- **Investigating gene expression profiles associated with clinical radiation resistance in KEAP1/NFE2L2 wildtype lung cancer.**
Binkley, M. S., Jeon, Y., Nesselbush, M., Moding, E. J., Nabet, B., Almanza, D., Yoo, C., Kurtz, D. M., Owen, S., Backhus, L. M., Berry, M. F., Shrager, J. B., Ramchandran, et al
AMER ASSOC CANCER RESEARCH.2021
- **Healthcare Utilization with an Electronic Patient Reported Outcome (ePRO) tool for Symptom Management in Thoracic Cancers**
Roy, M., Fardeen, T., Generalova, O., Hall, E., Cunanan, K., Das, M., Neal, J., Padda, S., Wakelee, H. A., Ramchandran, K.
ELSEVIER SCIENCE INC.2021: S170–S171
- **Giant Magnetoresistive Nanosensor Analysis of Circulating Tumor DNA Epidermal Growth Factor Receptor Mutations for Diagnosis and Therapy Response Monitoring.** *Clinical chemistry*
Nesvet, J. C., Antilla, K. A., Pancirer, D. S., Lozano, A. X., Preiss, J. S., Ma, W. n., Fu, A. n., Park, S. M., Gambhir, S. S., Fan, A. C., Neal, J. W., Padda, S. K., Das, et al
2021
- **Brief Report: Role of Consolidation Durvalumab in patients with EGFR and HER2 Mutant Unresectable Stage III NSCLC.** *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer*
Hellyer, J. A., Aredo, J. V., Das, M. n., Ramchandran, K. n., Padda, S. K., Neal, J. W., Wakelee, H. A.
2021
- **A noninvasive approach for early prediction of therapeutic benefit from immune checkpoint inhibition for lung cancer**
Nabet, B. Y., Esfahani, M. S., Hamilton, E. G., Chabon, J. J., Moding, E. J., Rizvi, H., Steen, C. B., Chaudhuri, A. A., Liu, C., Hui, A. B., Stehr, H., Goljenola, L., Jin, et al
AMER ASSOC CANCER RESEARCH.2020
- **Systemic Therapy of Extensive Stage Small Cell Lung Cancer in the Era of Immunotherapy.** *Current treatment options in oncology*
Ragavan, M., Das, M.
2020; 21 (8): 64
- **The Project Baseline Health Study: a step towards a broader mission to map human health** *NPJ DIGITAL MEDICINE*
Arges, K., Assimes, T., Bajaj, V., Balu, S., Bashir, M. R., Beskow, L., Blanco, R., Califf, R., Campbell, P., Carin, L., Christian, V., Cousins, S., Das, et al
2020; 3 (1): 84
- **The Project Baseline Health Study: a step towards a broader mission to map human health.** *NPJ digital medicine*
Arges, K., Assimes, T., Bajaj, V., Balu, S., Bashir, M. R., Beskow, L., Blanco, R., Califf, R., Campbell, P., Carin, L., Christian, V., Cousins, S., Das, et al
2020; 3 (1): 84
- **Advances in the Treatment of Stage III Non-Small Cell Lung Cancer.** *Clinics in chest medicine*
Myall, N. J., Das, M.
2020; 41 (2): 211–22

- **KEAP1/NFE2L2 mutations to predict local recurrence after radiotherapy but not surgery in localized non-small cell lung cancer.**
Binkley, M. S., Jeon, Y., Nesselbush, M., Moding, E. J., Nabet, B., Almanza, D. S., Yoo, C., Kurtz, D., Owen, S., Backhus, L., Berry, M. F., Shrager, J. B., Ramchandran, et al
AMER SOC CLINICAL ONCOLOGY.2020
- **A mid-chemoradiation dynamic risk model integrating tumor features and ctDNA analysis for lung cancer outcome prediction.**
Moding, E. J., Esfahani, M., Nabet, B., Liu, Y., Chabon, J. J., He, J., Qiao, Y., Xu, T., Yao, L., Gandhi, S., Liao, Z. X., Das, M., Ramchandran, et al
AMER SOC CLINICAL ONCOLOGY.2020
- **Circulating Tumor DNA Dynamics Predict Benefit from Consolidation Immunotherapy in Locally Advanced Non-Small Cell Lung Cancer.** *Nature cancer*
Moding, E. J., Liu, Y., Nabet, B. Y., Chabon, J. J., Chaudhuri, A. A., Hui, A. B., Bonilla, R. F., Ko, R. B., Yoo, C. H., Gojenola, L., Jones, C. D., He, J., Qiao, et al
2020; 1 (2): 176-183
- **Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition.** *Cell*
Nabet, B. Y., Esfahani, M. S., Moding, E. J., Hamilton, E. G., Chabon, J. J., Rizvi, H. n., Steen, C. B., Chaudhuri, A. A., Liu, C. L., Hui, A. B., Almanza, D. n., Stehr, H. n., Gojenola, et al
2020
- **Circulating tumor DNA dynamics predict benefit from consolidation immunotherapy in locally advanced non-small-cell lung cancer** *NATURE CANCER*
Moding, E. J., Liu, Y., Nabet, B. Y., Chabon, J. J., Chaudhuri, A. A., Hui, A. B., Bonilla, R. F., Ko, R. B., Gojenola, L., Jones, C. D., He, J., Qiao, Y., Heymach, et al
2020; 1: 176–183
- **A PHASE IIA STUDY REPOSITIONING DESIPRAMINE IN SMALL CELL LUNG CANCER AND OTHER HIGH-GRADE NEUROENDOCRINE TUMORS.** *Cancer treatment and research communications*
Riess, J. W., Jahchan, N. S., Das, M. n., Zach Koontz, M. n., Kunz, P. L., Wakelee, H. A., Schatzberg, A. n., Sage, J. n., Neal, J. W.
2020; 23: 100174
- **KEAP1/NFE2L2 mutations predict lung cancer radiation resistance that can be targeted by glutaminase inhibition.** *Cancer discovery*
Binkley, M. S., Jeon, Y. J., Nesselbush, M. n., Moding, E. J., Nabet, B. Y., Almanza, D. n., Kunder, C. n., Stehr, H. n., Yoo, C. H., Rhee, S. n., Xiang, M. n., Chabon, J. J., Hamilton, et al
2020
- **Feasibility and design of a cloud-based digital platform in patients with advanced cancer.**
Roy, M., Hall, E., Velazquez, B., Shah, S., Fardeen, T., Cunanan, K., San Pedro-Salcedo, M., Wakelee, H. A., Neal, J. W., Padda, S., Das, M., Fan, A. C., Srinivas, et al
AMER SOC CLINICAL ONCOLOGY.2019
- **Circulating Tumor DNA Changes During Chemoradiation for Lung Cancer Predict Patient Outcomes**
Moding, E. J., Nabet, B. Y., Liu, Y., Chabon, J. J., Chaudhuri, A. A., Hui, A. B., Binkley, M. S., He, J., Qiao, Y., Xu, T., Yao, L., Gandhi, S., Liao, et al
ELSEVIER SCIENCE INC.2019: S113
- **Impact of KEAP1/NFE2L2/CUL3 mutations on duration of response to EGFR tyrosine kinase inhibitors in EGFR mutated non-small cell lung cancer.** *Lung cancer (Amsterdam, Netherlands)*
Hellyer, J. A., Stehr, H. n., Das, M. n., Padda, S. K., Ramchandran, K. n., Neal, J. W., Diehn, M. n., Wakelee, H. A.
2019; 134: 42–45
- **Role of KEAP1/NFE2L2 mutations in the chemotherapeutic response of non-small cell lung cancer patients.** *Clinical cancer research : an official journal of the American Association for Cancer Research*
Jeong, Y. n., Hellyer, J. A., Stehr, H. n., Hoang, N. T., Niu, X. n., Das, M. n., Padda, S. K., Ramchandran, K. n., Neal, J. W., Wakelee, H. A., Diehn, M. n.
2019
- **Invasive nodal evaluation prior to stereotactic ablative radiation for non-small cell lung cancer.** *Lung cancer (Amsterdam, Netherlands)*
Harris, J. P., Nwachukwu, C., Qian, Y., Pollom, E., Loo, B. W., Das, M., Diehn, M.
2018; 124: 76–85
- **Invasive nodal evaluation prior to stereotactic ablative radiation for non-small cell lung cancer** *LUNG CANCER*

- Harris, J. P., Nwachukwu, C., Qian, Y., Pollom, E., Loo, B. W., Das, M., Diehn, M.
2018; 124: 76–85
- **A safety, tolerability, and pharmacokinetic analysis of two phase I studies of multitargeted small molecule tyrosine kinase inhibitor XL647 with an intermittent and continuous dosing schedule in patients with advanced solid malignancies** *CANCER CHEMOTHERAPY AND PHARMACOLOGY*
Das, M., Padda, S. K., Frymoyer, A., Molina, J., Adjei, A., Lensing, J. L., Miles, D., Sikic, B. I., Wakelee, H. A.
2018; 82 (3): 541–50
 - **A safety, tolerability, and pharmacokinetic analysis of two phase I studies of multitargeted small molecule tyrosine kinase inhibitor XL647 with an intermittent and continuous dosing schedule in patients with advanced solid malignancies.** *Cancer chemotherapy and pharmacology*
Das, M., Padda, S. K., Frymoyer, A., Molina, J., Adjei, A., Lensing, J. L., Miles, D., Sikic, B. I., Wakelee, H. A.
2018
 - **Circulating Tumor DNA Quantitation for Early Response Assessment of Immune Checkpoint Inhibitors for Metastatic Non-Small Cell Lung Cancer**
Chaudhuri, A. A., Nabet, B. Y., Merriott, D. J., Jin, M., Chen, E. L., Chabon, J. J., Newman, A. M., Stehr, H., Say, C., Carter, J. N., Walters, S., Becker, H., Das, et al
ELSEVIER SCIENCE INC.2018: E1–E2
 - **Circulating Tumor DNA Quantitation for Early Response Assessment of Immune Checkpoint Inhibitors for Lung Cancer**
Merriott, D. J., Chaudhuri, A. A., Jin, M., Chabon, J. J., Newman, A., Stehr, H., Say, C., Carter, J. N., Walters, S., Becker, H. R., Das, M., Padda, S., Loo, et al
ELSEVIER SCIENCE INC.2017: S20–S21
 - **Patterns of Care and Health Disparities for Patients With Stage I Non-small Cell Lung Cancer in the US**
Harris, J. P., Nwachukwu, C. R., Loo, B. W., Das, M., Diehn, M.
ELSEVIER SCIENCE INC.2017: E399
 - **Diagnosis and Treatment of Adenocarcinomas and Squamous Cell Carcinomas of the Lung.** *Journal of the advanced practitioner in oncology*
Das, M., Tisch, A. H.
2017; 8 (3): 267–72
 - **ERBB2-Mutated Metastatic Non-Small Cell Lung Cancer: Response and Resistance to Targeted Therapies.** *Journal of thoracic oncology*
Chuang, J. C., Stehr, H., Liang, Y., Das, M., Huang, J., Diehn, M., Wakelee, H. A., Neal, J. W.
2017
 - **Dovitinib and erlotinib in patients with metastatic non-small cell lung cancer: A drug-drug interaction** *LUNG CANCER*
Das, M., Padda, S. K., Frymoyer, A., Zhou, L., Riess, J. W., Neal, J. W., Wakelee, H. A.
2015; 89 (3): 280-286
 - **Angiogenesis and lung cancer: ramucirumab prolongs survival in 2(nd)-line metastatic NSCLC.** *Translational lung cancer research*
Das, M., Wakelee, H.
2014; 3 (6): 397-399
 - **A multicenter randomized phase II trial of erlotinib with and without hydroxychloroquine (HCQ) in TKI-naive patients (pts) with epidermal growth factor receptor (EGFR) mutant advanced non-small cell lung cancer (NSCLC)**
Neal, J. W., Wakelee, H. A., Feliciano, J., Goldberg, S. B., Morgensztern, D., Das, M., Heist, R., Lennes, I., Muzikansky, A., Edelman, M. J., Gettinger, S. N., Sequist, L. V.
AMER SOC CLINICAL ONCOLOGY.2014
 - **Assessment of patients' satisfaction of an innovative oncology telemedicine clinic.**
Nguyen, K., El-Masry, M., Tham, M., Howard, L., Ventura, R., Chwick, K., Das, M.
AMER SOC CLINICAL ONCOLOGY.2014
 - **Anti-angiogenic Agents in Metastatic NSCLC** *LUNG CANCER, 4TH EDITION*
Das, M., Wakelee, H.
edited by Roth, J. A., Hong, W. K., Komaki, R. U., Tsao, A. S., Chang, J. Y., Blackmon, S. H.
2014: 527–40

- **ERLOTINIB (E) AND DOVITINIB (TKI258) (D) IN PATIENTS (PTS) WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC): A SIGNIFICANT PHARMACOKINETIC (PK) INTERACTION**
Das, M., Padda, S. K., Zhou, L., Frymoyer, A., Neal, J. W., Wakelee, H. A.
LIPPINCOTT WILLIAMS & WILKINS.2013: S1185–S1186
- **VIETNAMESE NON-SMALL CELL LUNG CANCER PATIENTS IN CALIFORNIA: MOLECULAR PROFILES AND CLINICAL CHARACTERISTICS**
Nguyen, K. H., Das, M., Ramchandran, K., Shrager, J., Merritt, R. E., Hoang, C., Burt, B., Tisch, A., Pagtama, J., Zehnder, J., Berry, G., Wakelee, H. A., Anh-Hoa Nguyen, et al
LIPPINCOTT WILLIAMS & WILKINS.2013: S208–S209
- **PALLIATIVE CARE AND ANTI-CANCER CARE INTEGRATION: DESCRIPTION OF THREE MODELS OF CARE DELIVERY AT A TERTIARY MEDICAL CENTER**
Ramchandran, K. J., Fronk, J., Trieu, S., Wakelee, H. A., Das, M., Neal, J. W., Harman, S., Dwyer, P., Bosch, J., Shaw, H., Safari, S., Oden, R., Morrison, et al
LIPPINCOTT WILLIAMS & WILKINS.2013: S1324
- **A Case Series of Lengthy Progression-Free Survival With Pemetrexed-Containing Therapy in Metastatic Non-Small-Cell Lung Cancer Patients Harboring ROS1 Gene Rearrangements.** *Clinical lung cancer*
Riess, J. W., Padda, S. K., Bangs, C. D., Das, M., Neal, J. W., Adrouny, A. R., Cherry, A., Wakelee, H. A.
2013; 14 (5): 592-595
- **A Case Series of NSCLC Patients with Different Molecular Characteristics and Choroidal Metastases Improvement in Vision with Treatment Including Pemetrexed and Bevacizumab** *JOURNAL OF THORACIC ONCOLOGY*
Riess, J. W., Nagpal, S., Das, M., Neal, J. W., Kim, J. W., Wakelee, H. A.
2013; 8 (2): E17-E18
- **Anti-angiogenic agents in Non-Small-Cell Lung Cancer (NSCLC): a perspective on the MONET1 (Motesanib NSCLC Efficacy and Tolerability) study** *JOURNAL OF THORACIC DISEASE*
Das, M., Wakelee, H.
2012; 4 (6): 558-561
- **Angiogenesis inhibitors.** *Journal of thoracic oncology*
Das, M., Wakelee, H.
2012; 7 (16): S397-8
- **BIOMARKERS FOR ANTI-ANGIOGENIC THERAPY**
Das, M., Wakelee, H.
ELSEVIER SCIENCE INC.2012: S442–S443
- **ERCC1 expression in circulating tumor cells (CTCs) using a novel detection platform correlates with progression-free survival (PFS) in patients with metastatic non-small-cell lung cancer (NSCLC) receiving platinum chemotherapy.** *Lung cancer*
Das, M., Riess, J. W., Frankel, P., Schwartz, E., Bennis, R., Hsieh, H. B., Liu, X., Ly, J. C., Zhou, L., Nieva, J. J., Wakelee, H. A., Bruce, R. H.
2012; 77 (2): 421-426
- **Angiogenesis Inhibitors** *JOURNAL OF THORACIC ONCOLOGY*
Das, M., Wakelee, H.
2011; 6 (11): S1801-S1802
- **Results from a Single Institution Phase II Trial of Concurrent Docetaxel/Carboplatin/Radiotherapy Followed by Surgical Resection and Consolidation Docetaxel/Carboplatin in Stage III Non-Small-Cell Lung Cancer** *CLINICAL LUNG CANCER*
Das, M., Donington, J. S., Murphy, J., Kozak, M., Eclov, N., Whyte, R. I., Hoang, C. D., Zhou, L., Le, Q., Loo, B. W., Wakelee, H.
2011; 12 (5): 280-285
- **Stage IIIB and IV NSCLC: Primary Therapy** *LUNG CANCER: A MULTIDISCIPLINARY APPROACH TO DIAGNOSIS AND MANAGEMENT*
Das, M., Wakelee, H., Kernstine, K., Reckamp, K.
2011: 183–95
- **Vascular Disrupting Agents** *JOURNAL OF THORACIC ONCOLOGY*
Das, M., Wakelee, H.
2010; 5 (12): S482-S483

- **Alternatives to Surgery for Early Stage Non-Small Cell Lung Cancer-Ready for Prime Time?** *CURRENT TREATMENT OPTIONS IN ONCOLOGY*

Das, M., Abdelmaksoud, M. H., Loo, B. W., Kothary, N.
2010; 11 (1-2): 24-35